The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Tesla CEO Elon Musk took to his social media platform X to unveil his most recent weight loss while using a blood sugar ...
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...